← back to search

Tom Taghon

University College Ghent · BE
Area of research
Immunology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, T-cell and B-cell Immunology, and Immunotherapy and Immune Responses.
h-index
47
citations
8,582
works
356
NIH funding
primary concept
Biology
email

Recent publications

HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia
Blood 2025cited by 12position: middledoi
T cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges
Journal of Clinical Investigation 2025cited by 0position: middledoi
A spatial human thymus cell atlas mapped to a continuous tissue axis
Nature 2024cited by 75position: middledoi
A spatial human thymus cell atlas mapped to a continuous tissue axis
bioRxiv (Cold Spring Harbor Laboratory) 2023cited by 19position: middledoi
IRF2 is required for development and functional maturation of human NK cells
Frontiers in Immunology 2022cited by 23position: middledoi
The RNA Atlas expands the catalog of human non-coding RNAs
Nature Biotechnology 2021cited by 161position: middledoi
T-BET and EOMES Accelerate and Enhance Functional Differentiation of Human Natural Killer Cells
Frontiers in Immunology 2021cited by 59position: middledoi
Integrated scRNA-Seq Identifies Human Postnatal Thymus Seeding Progenitors and Regulatory Dynamics of Differentiating Immature Thymocytes
Immunity 2020cited by 140position: lastdoi
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia
Cancer Discovery 2020cited by 101position: middledoi
The transcription factor ETS1 is an important regulator of human NK cell development and terminal differentiation
Blood 2020cited by 74position: middledoi
Large-scale circular RNA deregulation in T-ALL: unlocking unique ectopic expression of molecular subtypes
Blood Advances 2020cited by 50position: middledoi
PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis
Leukemia 2020cited by 26position: middledoi
Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition
Science Translational Medicine 2019cited by 109position: middledoi
SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival
Nature Communications 2018cited by 79position: middledoi
Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation
Cancer Discovery 2018cited by 38position: middledoi
A Murine Intestinal Intraepithelial NKp46-Negative Innate Lymphoid Cell Population Characterized by Group 1 Properties
Cell Reports 2017cited by 28position: middledoi
ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling
Nature Communications 2015cited by 88position: middledoi
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
Blood 2014cited by 272position: middledoi
The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia
Blood 2014cited by 196position: middledoi
Integrative Genomic and Transcriptomic Analysis Identified Candidate Genes Implicated in the Pathogenesis of Hepatosplenic T-Cell Lymphoma
PLoS ONE 2014cited by 64position: middledoi
The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia
Haematologica 2014cited by 45position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Pieter Van Vlierberghe · University of Technology Sydney10 papers (2014–2022) · 5 papers (2017–2022) · 5 papers (2017–2022)Jan Cools · KU Leuven4 papers (2014–2019) · 4 papers (2017–2022)Patrick Matthys · KU Leuven4 papers (2017–2022)Wouter Van Loocke · New York University4 papers (2014–2022) · 3 papers (2017–2021) · 3 papers (2014–2014) · 3 papers (2020–2022) · 3 papers (2020–2020)Bruce Poppe · Georgetown University3 papers (2014–2014) · 3 papers (2014–2020) · 3 papers (2020–2022) · 3 papers (2014–2020) · 3 papers (2020–2022)Filip Van Nieuwerburgh · Ghent University Hospital3 papers (2020–2022) · 2 papers (2014–2014)Yvan Saeys · Institute of Molecular Biology and Biotechnology2 papers (2017–2020) · 2 papers (2014–2014)